Rafael Holdings Reports Q3 Fiscal 2026 Results: Pivotal NPC Trial Completion and Financial Update
Key Highlights
- Completion of Last Patient Last Visit in Pivotal Phase 3 TransportNPC™ Trial: Rafael Holdings, Inc. (NYSE: RFL) announced the completion of the last patient visit in its Phase 3 TransportNPC™ trial for Niemann-Pick Disease Type C (NPC), a rare, fatal, and progressive genetic disorder. This marks a critical milestone in the company’s lead program and could be transformative for patients suffering from NPC, a disease with significant unmet medical need.
- Pre-NDA Meeting with FDA and Expedited Path Forward: Following a positive pre-NDA (New Drug Application) meeting with the FDA, Rafael Holdings believes it has a clear and expedited regulatory path. The company expects to submit its NDA in the second half of calendar 2026. This could potentially accelerate the timeline to market for Trappsol® Cyclo™, the lead candidate, and transition Rafael Holdings into a commercial-stage biotechnology company.
- Financial Position: As of April 30, 2026, Rafael Holdings reported cash and cash equivalents of \$30.5 million, providing a solid liquidity base as it advances its late-stage clinical program.
Detailed Financial Review
Third Quarter Fiscal 2026 (Three Months Ended April 30, 2026)
- Net Loss: Rafael Holdings reported a net loss attributable to the company of \$4.2 million, or \$0.08 per share, compared to a net loss of \$4.8 million, or \$0.19 per share, for the same period last year. The decrease in per-share loss reflects a higher share count following the acquisition of Cyclo Therapeutics in March 2025.
- Research & Development (R&D) Expenses: R&D expenses increased sharply to \$4.9 million, up from \$3.0 million a year ago, primarily due to the inclusion of Cyclo’s R&D activities post-acquisition.
- General & Administrative (G&A) Expenses: G&A expenses decreased to \$2.1 million from \$3.2 million, reflecting reduced payroll, stock-based compensation, and professional fees, partially offset by Cyclo’s expenses.
First Nine Months of Fiscal 2026 (Nine Months Ended April 30, 2026)
- Net Loss: Net loss attributable to Rafael Holdings was \$20.5 million, or \$0.40 per share, compared to \$18.4 million, or \$0.73 per share, in the prior year. The increase is mainly due to the consolidation of Cyclo Therapeutics’ expenses.
- R&D Expenses: R&D expenses surged to \$16.9 million from \$5.3 million, again reflecting Cyclo’s inclusion.
- G&A Expenses: G&A expenses declined to \$7.3 million from \$8.3 million, as reductions in payroll and stock-based compensation offset Cyclo’s expenses.
- Revenue: Total revenue was modest at \$630,000 for the nine months, with contributions from product sales and rental income. The company is not yet generating significant commercial revenue from its lead programs.
- Balance Sheet: The company reported total assets of \$92.0 million and total equity of \$80.8 million as of April 30, 2026. The cash position decreased from \$52.8 million at July 31, 2025, reflecting ongoing R&D spending.
Strategic and Pipeline Updates
- Lead Candidate – Trappsol® Cyclo™: The company’s lead asset is being evaluated for NPC1, with the pivotal Phase 3 trial now complete. This asset represents significant potential, given the lack of approved therapies for NPC.
- Path to Commercialization: With an expected NDA filing in the second half of 2026, Rafael Holdings is positioning itself as a commercial-stage biotech, which could unlock substantial long-term value for shareholders if regulatory approvals are secured.
- Other Assets: Rafael Holdings continues to hold interests in other clinical-stage and early-stage pharmaceutical companies and an orthopedic-focused medical device company, contributing to its diversified pipeline.
Potential Share Price Impact
The successful completion of the pivotal Phase 3 trial and the expectation of an NDA submission in 2H 2026 are both highly material and could significantly impact Rafael Holdings’ share price, especially if the FDA provides a favorable review. Investors should note the company’s sufficient cash runway, the increased R&D investment reflecting a maturing pipeline, and the strategic focus on rare disease therapeutics with high unmet need. These factors collectively position Rafael Holdings for a potential value inflection if Trappsol® Cyclo™ is approved and commercialized.
Risks and Forward-Looking Statements
While the progress is noteworthy, investors should remain aware of the inherent risks in drug development, including regulatory, clinical, and commercial challenges. The company’s forward-looking statements are subject to risks and uncertainties, including those detailed in its SEC filings.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Please consult the company’s official filings and your financial advisor before making investment decisions.
